Roche John C 4
4 · HANOVER INSURANCE GROUP, INC. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
Roche John C
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-04-01$77.91/sh+8,906$693,866→ 133,319.708 total - Exercise/Conversion
Common Stock Option (right to buy)
2025-04-01−8,906→ 0 totalExercise: $77.91Exp: 2026-02-23→ Common Stock (8,906 underlying) - Sale
Common Stock
2025-04-01$175.17/sh−8,906$1,560,064→ 124,413.708 total
Footnotes (4)
- [F1]Exercise of options scheduled to expire in February 2026 and resulting sale of shares reported were effected pursuant to a pre-established Rule 10b5-1 Trading Plan adopted on November 5, 2024.
- [F2]Does not include 14,454 shares held by the Reporting Person's spouse.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold at multiple prices ranging from $175 to $175.83. The Reporting Person undertakes to provide The Hanover Insurance Group, Inc. ("THG"), any security holder of THG, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The option, representing the right to purchase a total of 21,413 shares, vested 1/3 on each of 2/23/17, 2/23/18 and 2/23/19.